Johnson & Johnson has developed a vaccine that works differently than the Pfizer and Moderna vaccines and is highly effective for preventing moderate to severe COVID-19.
The COVID-19 vaccine from Johnson & Johnson uses existing technology that involves a virus called adenovirus, a common cause of respiratory infections. The DNA in the adenovirus is modified so that it produces a key part of the SARS-CoV-2 virus particle to which the body then develops an immune response. The adenovirus that delivers the SARS-CoV-2 DNA particle cannot multiply, so it does not cause infection. Because this system is based on stable DNA molecules, it does not require ultracold storage, making it easier to distribute.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Published Online: March 1, 2021. doi:10.1001/jama.2021.2927
Conflict of Interest Disclosures: Dr Creech reported receipt of personal fees from Altimmune, Horizon, Karius, Adaptive, Premier, and Astellas; receipt of grants from Merck, and serving as an investigator in the phase 3 clinical trials of the Moderna and Johnson & Johnson vaccines. No other disclosures were reported.
Source: Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.